Martin Olin will remain in his position during a transition period.

“On behalf of the Board of Directors, I want to thank him for his work and leadership over the last three years. Martin has since he joined navigated the company through a strategic transition and established a solid platform for the further development of bemcentinib. On behalf of the company, I wish him all the best in his new endeavors”, says Anders Tullgren, Chairman of BerGenBio.

The Board of Directors has initiated a succession process and will actively work with the management to support and review the business requirements.

“I have thoroughly enjoyed my past three years at BerGenBio. It has been a privilege to lead the company and contribute to developing a medicine that can potentially be of great importance to a large number of patients. The company has a very competent team and an exciting time ahead, and I will follow its path and progress closely,” says Martin Olin.